Absci nelle notizie
Creazione di farmaci basata sull'IA
Tamtam ha trovato 20 articoli recenti su Absci.
- Is Absci (ABSI) A Bargain On Its ABS 201 Phase 2 Trial Update?
- Absci (NASDAQ:ABSI) Shares Down 5.5% - Here's Why
- Absci Corporation (NASDAQ:ABSI) Stock Has Average Target Price of $13.71
- Phase 2 Trial Plans Could Be A Game Changer For Absci Stock (ABSI)
- Weekly Recap: ABS-201 Phase 2 STORYLINE and Needham $11 Buy
- Absci Expects to Initiate Mid-Stage Trial of ABS-201 for Endometriosis in Mid-2027
- Absci (NASDAQ:ABSI) Stock Jumps 6.1% - Still a Buy?
- Guggenheim reiterates Absci stock rating on endometriosis trial delay
- Absci Corporation $ABSI Shares Newly Acquired by Bank of America Corp DE
- Absci Stock In Focus As Phase 2 Trial Plan Takes Shape
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Absci (ABSI) Maps Out Phase 2 Trial, Is It Still 29% Undervalued?
- Absci Announces Preliminary Details for Phase 2 STORYLINE™ Trial of AI-Designed Antibody ABS-201™ for Endometriosis
- Endometriosis affects roughly 1 in 10 women of reproductive age. Absci plans a drug trial in about 150 patients.
- Absci Corporation Announces Preliminary Details for Phase 2 Storyline? Trial of Ai-Designed Antibody Abs-201? for Endometriosis
- Absci (NASDAQ:ABSI) Stock Price Down 8.3% - What's Next?
- Absci (NASDAQ:ABSI) Earns "Buy" Rating from Needham & Company LLC
- Needham reiterates Buy rating on Absci, $11 price target
- Absci (ABSI) Stock Looks Expensive Against Its Book Value
- Wall Street Analysts Predict a 28.3% Upside in ABSCI CORP (ABSI): Here's What You Should Know
Articoli raccolti da Tamtam e conservati quando riguardano l'azienda, dal più recente. Ognuno rimanda alla sua fonte.
Vendi ad aziende come Absci?
Tamtam trova le aziende in linea con il tuo cliente ideale, analizza ogni account e ti dice chi contattare e quando.
Trova aziende simili